Jeff Huber brings a rare combination of large-scale software engineering leadership from Google (where he led Ads, Maps, and early Workspace) and hands-on biotech company-building experience as founding CEO of GRAIL, the prominent early-cancer detection company. At Triatomic Capital, he focuses specifically on companies that sit at the intersection of AI infrastructure and life sciences applications, backing deals like Manifold Bio and Betteromics while serving as an active board member who helps bridge tech and biotech cultures.
About their Fund
Triatomic Capital is a venture fund that writes checks from $100k to $25M across early to growth stages, focusing on "century-defining themes" like next-gen compute, automated economy, new materials, engineered biology, and new energy—positioning itself as a cross-vertical applied AI specialist that looks for AI as an enabling layer in physical-world and life-science problems rather than software plays. The fund combines deep health-tech and healthcare systems experience with frontier-tech investing expertise, creating an unusual bridge between regulated health systems and cutting-edge AI/deep tech startups while investing globally across the US and Asia-Pacific markets in infrastructure-focused companies rather than consumer AI applications.
























.jpeg)







.jpeg)











































































.png)
























































































































.jpeg)









.jpeg)


















































































.jpeg)

